Psoriasis is a systemic chronic skin disorder characterized by excessive keratinocytes proliferation that results into thickened scaly plaques, itching and inflammatory changes in the epidermis and dermis. It is transmitted genetically but can be provoked by environmental factors.
It is found in approximately 2% of the population that primarily affects the skin and joints.
It is associated with other inflammatory disorders and autoimmune diseases (eg psoriatic arthritis, inflammatory bowel disease, coronary artery disease).
Generally, it begins as red scaling papules that coalesce to form round-to-oval plaques. The rashes are often pruritic and may be painful.
Treatment with biologic agents appears to increase the rate of skin and soft tissue infections among patients with psoriasis, reports a recent study. In addition, a signal exists suggesting a heightened risk for meningitis.
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is safe and effective in moderate-to-severe plaque psoriasis, providing a persistent and long-term clinical response through 108 weeks of treatment, reports a recent study.
Duration of psoriasis poses harmful effects on vascular inflammation and major adverse cardiovascular (CV) event (MACE), a recent study has found. This suggests that cumulative duration of exposure to low-grade chronic inflammation may fast-track vascular disease development and MACEs.
The likelihood of suicidal ideation, suicide attempts and completed suicides is substantially greater in patients with psoriasis, according to a recent study. Among these patients, those who are younger and whose psoriasis is more severe are at risk of suicidality.
New drug applications approved by US FDA as of 1 - 15 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The risk for viral reactivation with biologic therapies is negligible in low-risk patients without hepatitis seropositive for hepatitis B or C virus (HBV and HCV, respectively) core antibody, a recent study has found. However, biologic therapies pose a significant risk in patients with chronic HBV infection, stressing the need for antiviral prophylaxis.
The oral Janus kinase inhibitor tofacitinib demonstrates superior efficacy vs placebo after 16 weeks of treatment in Asian patients with moderate to severe psoriasis, according to the results of a phase III trial. Furthermore, the improvements may be sustained up to week 52, with no unexpected safety findings.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.